AuthorisedTherapeutic use (Phase IV)Interventional

Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial

Juvenile idiopathic arthritis (JIA) causes painful, swollen joints in children and teenagers. Many young people take powerful biological medicines called TNF inhibitors to keep their condition under control. When these medicines work well, the arthritis can become inactive, meaning there are no symptoms. However, doctors do not yet know the best next step once the disease is quiet. Is it better to stay on regular injections, or can patients safely reduce the dose and stop them? The Treat-JIA study compares these two approaches over 12 months. Half of the participants will keep taking their usual dose, while the other half will slowly lower their dose and stop. Doctors will monitor everyone closely to see if symptoms return and how quickly they can be treated. The results will help families make confident choices about stopping long-term injections.

At a glance

Status

Authorised

Phase

Therapeutic use (Phase IV)

Sponsor

Oslo Universitetssykehus HF

Enrolment target

Start

23 Jun 2026

Juvenil Idiopatic Arthritis

What is this study about?

Juvenile idiopathic arthritis (JIA) is a long-term condition where the body's immune system accidentally attacks healthy joints. This leads to swelling, stiffness, and pain. Modern biological medicines called TNF inhibitors—such as etanercept, adalimumab, or golimumab—work by blocking a specific protein that causes this inflammation. For many children and teenagers, these injections work very well and send their arthritis into a quiet, symptom-free state known as remission.

While reaching remission is fantastic news, continuing to take regular injections has downsides. Injections can be uncomfortable, time-consuming, and carry small risks like infections. Because of this, patients and their families often wonder if they can safely stop taking them. On the other hand, stopping the medicine might cause the arthritis to wake up again, leading to a flare-up of painful joints.

The Treat-JIA trial aims to solve this dilemma. It is a UK research study testing whether slowly tapering off (reducing) TNF inhibitors is as safe and effective as continuing them at the standard dose. By tracking participants over one year, researchers hope to give doctors clear, reliable guidance on when it is safe to stop treatment.

Key takeaways

Tests whether young people with quiet JIA can safely stop their biologic injections.
Compares staying on regular medication against slowly tapering it off.
Participants are followed closely by doctors for 12 months.
If arthritis flares up, treatment is quickly restarted to soothe your joints.
You can withdraw from the study at any time without losing any care.

Who may be eligible?

This study is open to children, teenagers, and young people of any age who have been diagnosed with juvenile idiopathic arthritis. To take part, your arthritis must have been inactive and quiet for a sustained period while taking a TNF inhibitor medicine on its own.

You cannot take part if your arthritis is currently causing symptoms like swollen or painful joints. It is also not suitable for patients who have only just started their treatment or whose condition has flared up recently.

Your hospital rheumatology team will carry out standard checks to see if your joints are completely calm and decide whether you are safe to join the study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I have been diagnosed with juvenile idiopathic arthritis (JIA).
I currently take a TNF inhibitor injection (such as Enbrel, Benepali, Hyrimoz, or Simponi).
My arthritis is currently inactive with no swollen or painful joints.
I have been stable on this medicine for an agreed period of time.
I am able to attend regular hospital check-ups for the next 12 months.

Answer every question to see your result.

What does participation involve?

Taking part lasts for 12 months. At the start, a computer will randomly place you into one of two groups. One group will stay on their normal injection schedule, while the other group will gradually reduce their injections until they stop taking them completely.

You will visit your hospital clinic for regular check-ups throughout the year. During these visits, doctors will gently examine your joints, ask about your daily life, and check for any side effects. You might also have standard blood tests. If your joint pain or swelling returns at any point during the trial, the medical team will act quickly to restart or adjust your treatment.

Potential risks and benefits

If you are in the reduction group, you might be able to stop having regular injections, saving you from discomfort and routine medication. However, reducing your treatment carries the risk that your arthritis could return (flare up). If this happens, your healthcare team will treat you straight away to regain control. Taking part is completely voluntary, and you can change your mind and leave the study at any time without your normal NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Norway

Common questions

What is a TNF inhibitor?

It is a biological medicine that blocks a protein called TNF in your body. This protein causes swelling and inflammation in conditions like arthritis.

What is a disease flare?

A flare is when arthritis symptoms return after being quiet. This usually means one or more joints become swollen, tender, or harder to move.

What happens if my arthritis flares up during the trial?

Your study doctor will see you right away. They will restart or increase your medication to get the swelling and pain back under control as quickly as possible.

Can I choose whether to reduce my injections?

No. A computer assigns you to a group by chance. This makes sure the study is completely fair and the scientific results are trustworthy.

Do I have to pay for anything?

No. All study medicines, appointments, and tests are provided as part of medical research within the NHS.